Business

Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health

Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026Diluted EPS of $3.91 and Adjusted Diluted EPS of $4.38 in fiscal year 2026Announces agreement to acquire LaCorium Health, a leader in Australian therapeutic skin careIntroducing Outlook for Fiscal 2027 Organic Revenue Growth and Adjusted Diluted EPS of 1% to 3%, respectively, excluding the impact of acquisitions TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today rep

articlePrestige Consumer Healthcare Inc.May 13, 202630/company/prestige-brand-holdings-inc/news/prestige-consumer-healthcare-inc-reports-fiscal-2026-results-announces-acquisition-of-lacorium-health
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health

About this update from Prestige Consumer Healthcare Inc.

[{"type":"image","alt":"Prestige Consumer Healthcare Inc.","displaySize":"","headline":null,"caption":"Prestige Consumer Healthcare Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/1b5655ca12a92f858081df51ed2ce36b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FLwmlDskH0PHRRLgz3xb6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1b5655ca12a92f858081df51ed2ce36b","width":300,"height":102},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/FLwmlDskH0PHRRLgz3xb6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1b5655ca12a92f858081df51ed2ce36b","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Diluted EPS of $3.91 and Adjusted Diluted EPS of $4.38 in fiscal year 2026","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Announces agreement to acquire LaCorium Health, a leader in Australian therapeutic skin care","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Introducing Outlook for Fiscal 2027 Organic Revenue Growth and Adjusted Diluted EPS of 1% to 3%, respectively, excluding the impact of acquisitions","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":395,"olType":false},{"type":"text","content":"TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026.","length":188,"tagName":"p"},{"type":"text","content":"“Our fiscal 2026 demonstrated the resilience of our business model in a challenging consumer backdrop.","length":102,"tagName":"p"},{"type":"text","content":"Our diversified portfolio of leading brands with deep consumer heritage supports a durable financial profile and drives strong, growing free cash flow. In fiscal 2026, this resulted in $246.4 million of free cash flow driven by continued strength that included strong growth for Fleet®, Dramamine®, and Hydralyte® in our Gastrointestinal category, which helped partially offset the impacts of limited eye care production as well as ...

More updates from Prestige Consumer Healthcare Inc.

fourth quarterPrestige Consumer Healthcarenet incomeDiluted earnings per shareNet Incomecomparable periodHealthcareThe Company